Truist Financial’s Trillium Therapeutics Inc. TRIL Stock Holding History

Truist Financial’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-52,722	Closed	-$926K	–	2909
2021 Q3	$926K	Buy	52,722 +1,000	+2%	+$11.7K	﹤0.01%	1658
2021 Q2	$502K	Sell	51,722 -4,000	-7%	-$37.6K	﹤0.01%	2047
2021 Q1	$598K	Hold	55,722	–	–	﹤0.01%	1874
2020 Q4	$820K	Buy	55,722 +26,500	+91%	+$382K	﹤0.01%	1585
2020 Q3	$444K	Buy	+29,222	New	+$291K	﹤0.01%	1784

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Truist Financial's TRIL Position: Q4 2021 in Review

Truist Financial sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 52,722 shares — an estimated $926K sold.

Truist Financial first reported a position in TRIL in Q3 2020 and held it in 5 quarters. The position peaked at $926K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Truist Financial reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Truist Financial sold 52,722 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $926K.
Truist Financial first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 5 quarters.
Truist Financial's Trillium Therapeutics Inc. position peaked at $926K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Truist Financial's 13F filing for Q4 2021, filed 14 Feb 2022.